Corticosteroid Use in ARDS after Influenza A in Patients with Multiple Myeloma
Contraindications for Corticosteroid Use
- The Infectious Diseases Society of America (IDSA) recommends against the use of adjunctive corticosteroid therapy for adults or children with suspected or confirmed influenza, influenza-associated pneumonia, respiratory failure, or ARDS, unless there is another clinical indication 1
Patient Characteristics to Consider
- Patients with multiple myeloma have underlying immune suppression due to their disease and treatment 2
- Patients with multiple myeloma are at higher risk for respiratory infections, including influenza, influenza A, and respiratory syncytial virus (RSV) 3
Exceptions for Corticosteroid Use
- In patients with early ARDS (within 14 days of onset) not related to influenza, methylprednisolone at a dose of 1 mg/kg/day may be considered 4, 5
- If patients have signs of critical illness-related corticosteroid insufficiency (CIRCI), hydrocortisone at a dose of <400 mg/day for ≥3 days may be considered 7
Alternative and Supportive Treatments
- Early antiviral treatment with neuraminidase inhibitors (NAIs) is recommended for patients with influenza A 1
- Empiric investigation and treatment of bacterial co-infections is recommended for patients with severe initial presentation (extensive pneumonia, respiratory failure, hypotension, and fever) 1
Special Considerations for Multiple Myeloma Patients
- Annual influenza vaccination is recommended for all multiple myeloma patients, their family members, and caregivers 2
- Vaccination should be administered before starting multiple myeloma treatment and before the start of each new influenza season 2
- Close monitoring for signs of infection is necessary, as multiple myeloma patients are at high risk for developing opportunistic infections 2, 3